FDA Approves Pivekimab Sunirine as First ADC for Ultra-Rare Blood Cancer BPDCN
核心洞察
The FDA has approved pivekimab sunirine-pvzy (搜索) (Decnupaz (搜索)) as the first antibody-drug conjugate for treating adult patients with blastic plasmacytoid dendritic cell neoplasm (搜索) (BPDCN (搜索)), an ultra-rare and aggressive blood cancer.
In the CADENZA trial, newly diagnosed BPDCN (搜索) patients achieved a 69.7% complete remission rate with a median duration of 9.7 months, while relapsed/refractory patients had a 15.7% response rate.
The CD123 (搜索)-targeting ADC can be administered in an outpatient setting and carries a boxed warning for hepatotoxicity, including potentially life-threatening hepatic veno-occlusive disease (搜索).
The FDA has approved pivekimab sunirine-pvzy (搜索) (Decnupaz (搜索)) for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (搜索) (BPDCN (搜索)), marking the first antibody-drug conjugate (ADC) approved for this ultra-rare and aggressive hematologic malignancy. The approval represents a significant milestone for AbbVie (搜索), as it is the company's first ADC approved for blood cancer.
Clinical Trial Results Drive Approval
The FDA based its approval on data from the single-arm phase 1/2 CADENZA trial (NCT03386513), which evaluated pivekimab sunirine in 84 patients with BPDCN (搜索) across treatment-naive and relapsed/refractory settings. In the treatment-naive cohort of 33 patients, the drug demonstrated a complete remission (CR)/clinical complete remission (CRc) rate of 69.7% (95% CI, 51.3%-84.4%) after a median follow-up of 21.5 months. The median duration of CR/CRc was 9.7 months (95% CI, 2.9-not estimable).
"In newly diagnosed patients with BPDCN (搜索) (n=33), researchers observed a composite complete response rate of 69.7% with a median duration of response of 9.7 months, with 13 patients (39.4%) who were able to receive post-study treatment stem cell transplant," according to AbbVie (搜索)'s announcement.
For patients with relapsed or refractory disease (n=51), the CR/CRc rate was 15.7% (95% CI, 7.0%-28.6%) after a median follow-up of 24.1 months, with a median duration of CR/CRc of 9.2 months. Six patients (11.8%) in this group were able to receive post-study treatment stem cell transplant.
Addressing an Unmet Medical Need
BPDCN (搜索) is an ultra-rare and aggressive hematologic malignancy that typically affects adult men aged 60-70 years. Patients often present with skin lesions, and the disease can rapidly spread to the bone marrow, lymph nodes, and central nervous system. Despite initial treatment with intensive chemotherapy, which may include stem cell transplantation, many patients experience relapse.
"BPDCN (搜索) is an aggressive disease with historically limited therapeutic options, particularly for patients whose disease has relapsed or become refractory," said Naveen Pemmaraju, M.D., professor of leukemia at The University of Texas MD Anderson Cancer Center. "Pivekimab sunirine-pvzy (搜索) is the first and only CD123 (搜索) targeting ADC that can be initiated in an outpatient setting, offering a meaningful benefit for BPDCN patients in need of new treatment alternatives."
Mechanism of Action and Dosing
Pivekimab sunirine is a CD123 (搜索)-targeting ADC designed to deliver potent cell death-inducing agents directly to cells expressing CD123 (IL-3Rα (搜索)), a protein overexpressed in BPDCN (搜索). The payload is a member of the indolinobenzodiazepine pseudodimer class that alkylates DNA and causes single-strand DNA breaks without crosslinking, leading to apoptosis and cell death.
The FDA approved pivekimab sunirine at a dose of 0.045 mg/kg intravenously for approximately 15 to 30 minutes once every 3 weeks until progressive disease or unacceptable toxicity.
Safety Profile and Warnings
The prescribing information for pivekimab sunirine includes a Boxed Warning for hepatotoxicity, including hepatic veno-occlusive disease (搜索), which can be severe, life-threatening, or lead to death. Additional warnings cover infusion-related reactions, sulfite allergic reactions, edema, and embryo-fetal toxicity.
The most common adverse reactions (≥20%) observed in the trial were edema, fatigue, musculoskeletal pain, hemorrhage, infusion-related reactions, nausea, and diarrhea. Healthcare providers will conduct blood tests before each dose and during treatment to monitor for liver problems.
Regulatory Timeline and Development
The FDA previously received a biologics license application for pivekimab sunirine in this BPDCN (搜索) population in September 2025. In October 2020, the FDA had granted pivekimab sunirine Breakthrough Therapy Designation for relapsed/refractory BPDCN, recognizing the significant unmet medical need in this patient population.
"For patients living with rare cancers, progress in research can be life‑changing," said Roopal Thakkar, executive vice president, research and development, chief scientific officer at AbbVie (搜索). "This approval delivers a new option for treating BPDCN (搜索) and demonstrates our determination to drive meaningful advancements for patients affected by difficult-to-treat cancers."